Phase III clinical trial of BTI 320 [PAZ 320] for type 2 diabetes mellitus

Trial Profile

Phase III clinical trial of BTI 320 [PAZ 320] for type 2 diabetes mellitus

Planning
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs BTI 320 (Primary) ; CD26 antigen inhibitors; Insulins; Metformin; Sulfonylureas
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Boston Therapeutics
  • Most Recent Events

    • 26 Apr 2017 According to a Boston Therapeutics media release, recruitment will initiate at the Joslin Diabetes Center, Boston, MA, and will be joined by its former trial center form the Chinese University of Hong Kong (CUHK) . The plans anticipate up to 10 additional institutions from the US and greater China.
    • 10 Dec 2014 The US FDA has accepted the IND for this trial, according to a Boston Therapeutics media release.
    • 06 May 2014 Status changed from unconfirmed to planning, according to a Boston Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top